Welcome to Alt-Support-Diabetes.org

Alt-Support-Diabetes.org is under new management.

The previous webmaster was discouraged by the lack of interest in the site, and the death of Usenet in general. The active members in the alt.support.diabetes newsgroup weren't even referring to it anymore.

The domain registration for Alt-Support-Diabetes.org was paid years in advance by Mack, who was a frequent poster on the alt.support.diabetes newsgroup and an Alt-Support-Diabetes.org Webmaster. So it doesn't make sense to have a "We're shutdown" message for the next several years. However, it's probable the site will disappear on 12 April 2024.

Some of the information here is very old as the original site was established in 2001 and much of it has never been updated. But it's still a valuable resource. So it's back.

If you would like to contribute content for the site, please contact the ASD Webmaster. Articles attributed to ASD Webmaster as contributor are those for which the true author cannot be determined. If you know who should be credited, please let us know.

Alt-Support-Diabetes (ASD) is an online support group of diabetics, their families and friends. We use this forum to freely share our personal experiences, knowledge, hopes, successes and frustrations concerning diabetes and it's impact on our lives. Currently we are using three major forums: the newsgroup alt.support.diabetes, our IRC chat room, and this website.

Newsgroups are one of the oldest parts of the internet called UseNet. It even pre-dates the World Wide Web. Currently there are over 70,000 individual newsgroups.

We encourage everyone to first read the Newsgroups FAQ. It explains the few do's and don'ts and some basic information about posting to a UseNet forum such as ours.

Disclaimer

The information made available through this web site is not intended to replace the services of a physician. It is provided for informational purposes only and is not a substitute for professional medical advice.

Diabetes News from MIT

29 November 2023

MIT news feed about: Diabetes

Diabetes News from ScienceDaily

29 November 2023

Learn about early diabetes symptoms, diabetic diet information, diabetes care, type 1 diabetes, insulin resistance and type 2 diabetes. Read the latest medical research on diabetes.
  • Stem cell-based treatment controls blood sugar in people with Type 1 diabetes
    An innovative stem cell-based treatment for Type 1 diabetes can meaningfully regulate blood glucose levels and reduce dependence on daily insulin injections, according to new clinical trial results. The therapy aims to replace the insulin-producing beta cells that people with Type 1 diabetes lack. Dubbed VC-02, the small medical implant contains millions of lab-grown pancreatic islet cells, including beta cells, that originate from a line of pluripotent stem cells.
  • Novel molecular mechanisms in the early development of diabetes mellitus
    Researchers conducted a gene expression analysis at the single-cell level on pancreatic islets from prediabetic and diabetic mouse models. Analysis results revealed upregulation of Anxa10 expression in pancreatic beta cells during the early phases of diabetes, attributed to elevated blood glucose levels. This elevated Anxa10 expression was found to influence intracellular calcium homeostasis, leading to a reduction in insulin secretory capacity.
  • Hormones have the potential to treat liver fibrosis
    Researchers have discovered previously unknown changes in a specific type of liver cells, potentially opening avenues for a new treatment for liver fibrosis, a potentially life-threatening condition. Currently, there are no drugs available to treat liver fibrosis.
  • NHS Diabetes Prevention Programme may have global impact
    As ten percent of the world's adult population is predicted to have diabetes by 2030, a major new study finds that the NHS Diabetes Prevention Programme has a positive effect on reducing risk of developing diabetes.
  • Semaglutide reduced cardiovascular events by 20% in certain adults
    Semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes, according to new research.   Semaglutide is primarily prescribed for adults with type 2 diabetes but is also approved for chronic weight management in adults with obesity or overweight and have at least one other health issue. In the trial, patients treated with semaglutide lost an average of 9.4% of their body weight and experienced improvements in other risk factors for cardiovascular disease.   Results from the 'SELECT -- Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes' trial were presented today during a late-breaking science session at the American Heart Association's Scientific Sessions 2023 and simultaneously published in the New England Journal of Medicine.